Analyst Reco. Voyager Therapeutics, Inc.

Equities

VYGR

US92915B1061

Real-time Estimate Cboe BZX Other stock markets 16:13:47 03/05/2024 BST			5-day change	1st Jan Change
8.705 ^USD	+2.05%		+14.67%	+3.53%

04-02	Voyager Therapeutics, Inc. Appoints Robin Swartz as Principal Accounting Officer	CI
04-02	Voyager Therapeutics, Inc. Announces CFO Changes	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Guggenheim Initiates Voyager Therapeutics With Buy Rating, $22 Price Target	03-26	MT
H.C. Wainwright Initiates Coverage on Voyager Therapeutics With Buy Rating, $30 Price Target	03-19	MT
Citigroup Starts Voyager Therapeutics With Buy Rating, $16 Price Target	03-07	MT
Wedbush Trims Voyager Therapeutics' Price Target to $10 From $11, Neutral Rating Kept	01-05	MT
US job data raises doubts about the Fed's next moves	01-05
Wedbush Lifts Voyager Therapeutics' PT to $11 From $10, Says New Agreement With Novartis Unit Generate More Non-Dilutive Capital To Start Year; Keeps Neutral Rating	01-02	MT
Truist Starts Voyager Therapeutics at Buy With $18	10/05/23	MT
Oppenheimer Initiates Coverage on Voyager Therapeutics With Outperform Rating, $14 Price Target	10/03/23	MT
Wedbush Raises Voyager Therapeutics' Price Target to $10 From $4, Keeps Neutral Rating	09/01/23	MT
Wedbush Adjusts Voyager Therapeutics Price Target to $4 From $3, Maintains Neutral Rating	04/10/22	MT
Wedbush Cuts Price Target on Voyager Therapeutics to $3 From $4 on 'Lower Net Cash,' Maintains Neutral Rating	05/05/22	MT
Chardan Research Adjusts Price Target on Voyager Therapeutics to $6 From $4; Neutral Rating Kept	09/03/22	MT
Wedbush Adjusts Voyager Therapeutics Price Target to $4 From $3, Maintains Neutral Rating	08/03/22	MT
Chardan Adjusts Price Target on Voyager Therapeutics to $4 From $5.50 While Awaiting Info on New Pipeline, Maintains Neutral Rating	03/11/21	MT
VOYAGER THERAPEUTICS : Baird Upgrades Voyager Therapeutics to Outperform from Neutral, Adjusts Price Target to $9 from $6	07/10/21	MT
VOYAGER THERAPEUTICS : Wedbush Adjusts Voyager Therapeutics' PT to $3 From $6, Citing Profit Share Arrangement, Potential Secondary Offering Size; Neutral Rating Kept	11/05/21	MT
VOYAGER THERAPEUTICS : Baird Downgrades Voyager Therapeutics to Neutral From Outperform, Adjusts Price Target to $6 From $18	26/02/21	MT
Chardan Adjusts Price Target on Voyager Therapeutics to $6.50 From $15, Maintains Neutral Rating	03/02/21	MT
VOYAGER THERAPEUTICS : Chardan Adjusts Price Target on Voyager Therapeutics to $6.50 From $15, Maintains Neutral Rating	03/02/21	MT
VOYAGER THERAPEUTICS : Morgan Stanley Adjusts Price Target on Voyager Therapeutics to $7 From $13, Keeps Equal-Weight Rating	03/02/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Voyager Therapeutics, Inc.

Equities

VYGR

US92915B1061

Analyst Reco.

Filters